WallStSmart
MAIA

MAIA Biotechnology Inc.

AMEX: MAIA · HEALTHCARE · BIOTECHNOLOGY

$1.32
-9.33% today

Updated 2026-06-05

Market cap
$82.69M
P/E ratio
P/S ratio
EPS (TTM)
$-0.68
Dividend yield
52W range
$1 – $3
Volume
0.8M

MAIA Biotechnology Inc. (MAIA) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item2019202020212022202320242025
Total assets$1.73M$746505.00$11.33M$12.02M$7.57M$10.16M$9.70M
Cash & equivalents$1.71M$663457.00$10.57M$10.95M$7.15M$9.60M$8.66B
Current assets$1.73M$746505.00$10.67M$11.81M$7.56M$10.15M$9.70M
Total liabilities$409737.00$2.36M$2.15M$3.51M$7.09M$6.52M$7.33M
Current liabilities$374565.00$1.69M$2.15M$3.27M$4.94M$3.83M$5.84M
Long-term debt$431801.00
Shareholder equity$-172867.00$-3.34M$9.18M$8.51M$477511.00$3.63M$2.38M
Retained earnings$-9.30M$-15.93M$-28.44M$-44.21M$-63.98M$-87.23M$-109.63M
Accounts receivable$43666.00$302789.00$144680.00$77347.00
Inventory$-43666.00
Goodwill

Frequently asked questions

How much free cash flow does MAIA generate?

MAIA produced $-18.84M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is MAIA's balance sheet healthy?

MAIA holds $8.66B in cash and equivalents against — in long-term debt, on $2.38M of shareholder equity. That debt is best read against the cash flow the business throws off each year.